Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) – Research analysts at Wedbush issued their Q4 2016 earnings per share estimates for Achillion Pharmaceuticals in a research report issued on Thursday. Wedbush analyst H. Behanna expects that the brokerage will post earnings of ($0.15) per share for the quarter. Wedbush currently has a “Outperform” rating and a $13.00 target price on the stock. Wedbush also issued estimates for Achillion Pharmaceuticals’ FY2017 earnings at ($0.68) EPS and FY2020 earnings at ($0.43) EPS.
Several other analysts have also weighed in on the company. Chardan Capital raised their price objective on Achillion Pharmaceuticals from $4.00 to $5.00 and gave the company a “sell” rating in a research note on Friday. Robert W. Baird reaffirmed an “outperform” rating and issued a $10.00 price objective on shares of Achillion Pharmaceuticals in a research note on Monday, June 6th. FBR & Co assumed coverage on Achillion Pharmaceuticals in a research note on Thursday, September 15th. They issued an “outperform” rating and a $16.00 price objective on the stock. Leerink Swann reaffirmed a “hold” rating on shares of Achillion Pharmaceuticals in a research note on Sunday, June 12th. Finally, JMP Securities raised Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $13.00 price objective on the stock in a research note on Thursday, July 7th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $10.70.
Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) opened at 8.69 on Monday. Achillion Pharmaceuticals has a 52 week low of $5.57 and a 52 week high of $10.95. The stock has a 50 day moving average price of $8.48 and a 200-day moving average price of $8.41. The company has a market capitalization of $1.19 billion, a PE ratio of 177.35 and a beta of 2.21.
Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. During the same period in the prior year, the firm earned ($0.25) earnings per share.
Institutional investors have recently bought and sold shares of the company. RTW Investments LLC raised its position in Achillion Pharmaceuticals by 31.1% in the first quarter. RTW Investments LLC now owns 2,558,859 shares of the biopharmaceutical company’s stock worth $19,754,000 after buying an additional 606,937 shares in the last quarter. Vanguard Group Inc. raised its position in Achillion Pharmaceuticals by 5.7% in the second quarter. Vanguard Group Inc. now owns 8,454,713 shares of the biopharmaceutical company’s stock worth $65,947,000 after buying an additional 455,251 shares in the last quarter. Bellevue Group AG bought a new position in Achillion Pharmaceuticals during the first quarter worth approximately $3,242,000. Emerald Acquisition Ltd. bought a new position in Achillion Pharmaceuticals during the second quarter worth approximately $1,393,000. Finally, BlackRock Institutional Trust Company N.A. raised its position in Achillion Pharmaceuticals by 4.7% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 3,021,403 shares of the biopharmaceutical company’s stock worth $23,567,000 after buying an additional 136,258 shares in the last quarter. 79.43% of the stock is currently owned by institutional investors.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.